Chinese General Practice

Previous Articles     Next Articles

Drug-Induced Cardiotoxicity in the Chinese Population:Current Analysis and Considerations

  

  1. 1.Heart Center,The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China;2.The First Clinical Medical College,Henan University of Chinese Medicine,Zhengzhou 450000,China;3.Henan Center for Evidence-based Medicine of Chinese Medicine,Zhengzhou 450000,China
  • Contact: LI Bin,Associate chief physician;E-mail:libinnvhai@163.com

中国人群药源性心脏毒性的现状分析与展望

  

  1. 1.450000 河南省郑州市,河南中医药大学第一附属医院心脏中心;2.450000 河南省郑州市,河南中医药大学第一临床医学院;3.450000 河南省郑州市,河南省中医药循证医学中心
  • 通讯作者: 李彬,主任医师,E-mail:libinnvhai@163.com
  • 基金资助:
    国家自然科学基金项目(82074226);河南省中医药科学研究专项(2024ZY2013,2023ZXZX1165,2022JDZX120);河南省科技攻关(No:222102310332)

Abstract: Pharmacogenetic cardiotoxicity is one of the most common and serious clinical adverse drug reactions and an important risk factor for cardiovascular disease. At present,highly specific and sensitive early predictive indicators and effective preventive and curative drugs are still lacking. It is of great significance to understand the current situation of the occurrence of drug-induced cardiotoxicity in China,to explore the clinical evaluation indices for early detection,and to summarize the measures to reduce toxicity and increase efficacy in order to improve cardiac injury and enhance drug safety. The purpose of this paper is to systematically summarize the clinical status of drug-induced cardiotoxicity in China,list in detail the drugs with definite or potential cardiotoxicity,and explore the mechanisms of their toxicity. At the same time,it focuses on the early monitoring and warning of drug-induced cardiotoxicity,and summarizes the prevention and treatment measures in Chinese and Western medicine,which provide valuable references for its early detection and early intervention.

Key words: Drug-related side effects and adverse reactions, Cardiotoxicity, Drug-induced cardiotoxicity, Drug safety, China

摘要: 药源性心脏毒性是临床中常见且相对严重的药物不良反应,同时也是导致心血管疾病发生、发展的重要风险因素。尽管如此,目前的临床实践中仍缺乏高度特异性、敏感性的早期预测指标及有效的防治药物。了解我国药源性心脏毒性的发生现状,探索早期发现的临床评价指标,归纳减毒增效的措施对于改善心脏损伤、提高药物安全性具有重大意义。本文旨在系统总结我国药源性心脏毒性的临床现状,详细列举已明确或潜在具有心脏毒性的药物,并探讨其毒性产生的机制。同时,重点关注药源性心脏毒性的早期监测预警,总结了中西医防治措施,为其早期发现、早期干预提供有价值的参考。

关键词: 药物相关性副作用和不良反应, 心脏毒性, 药源性心脏毒性, 药物安全, 中国

CLC Number: